Juan Carlos Jaume Lab

Juan Carlos Jaume, MD — Publications

Image result for nature group publishing
TWO (2) NATURE GROUP PAPERS PUBLISHED BACK-TO-BACK THIS NEW YEAR 2019!

1-Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer.

2-eIF5A inhibition influences T cell dynamics in the pancreatic microenvironment of the humanized mouse model of Type 1 Diabetes.


 

Journal Peer Reviewed | Study Sections | Invited LecturesPatents
BibliographyInvited Articles, Books and Book Chapters | Abstracts


 Journal Peer Review

  • Journal of Clinical Endocrinology and Metabolism
  • Thyroid
  • Endocrine Related Cancer
  • Annals of Surgical Oncology
  • Hormones and Cancer (Editorial Board)

STUDY SECTIONS, REVIEW PANELS

2003-2008 Endocrinology A Study Section. Veterans Administration. Washington, DC
09/14/04 Infection and Immunity. The Wellcome Trust. London, United Kingdom
11/01/04 Ophthalmology Study Section. National Eye Institute. NIH. Bethesda, MD
04/07/14 Diabetes Study Section, NIDDK, NIH, Bethesda, MD
2015-2018 Diabetes Study Section, MDRC, University of Michigan, Ann Arbor, MI


INVITED LECTURES, SEMINARS, SYMPOSIA, VISITING PROFESSORSHIPS

  • 10/23/1991  UCSF / VAMC.  Endocrinology/Metabolism Grand Rounds.  “Growth Hormone in the Elderly"
  • 02/23/1994  UCSF / VAMC.  Endocrinology/Metabolism Grand Rounds.  “New Approaches for the Study of Graves' Ophthalmopathy”
  • 03/20/1995  UCSF. Molecular Medicine Annual Conference. “Molecular Cloning and Characterization of Genes for Antibodies Generated by Tissue-Infiltrating B Cells in Graves' Ophthalmopathy”
  • 05/23/1996  UCSF. Molecular Medicine Annual Conference. “Epitopic Fingerprints of Human Monoclonal Autoantibodies to a Major Organ-Specific Autoantigen: Evidence for Conservation Over Time and in Families”
  • 09/02/1998  Kaiser Permanente Medical Centers of Walnut Creek, Martinez, Antioch and Park Shadelands.  “Thyroid conditions in women”
  • 12/07/2001  Yale University.  Endocrinology Grand Rounds. “How epitope specificity of autoimmune B cells affects peptide presentation to T cells”
  • 05/08/2002  Stanford University.  Endocrinology Grand Rounds.  “B cell epitope modulation of T cell determinants in thyroid disease and diabetes”
  • 07/11/2002  University of Wisconsin-Madison.  Endocrinology Grand Rounds.  “Role of autoantibodies in thyroid disease and diabetes”
  • 06/05/2002  UCSF.  Endocrinology Grand Rounds.  “Antigen presentation in thyroid disease and diabetes”
  • 04/14/05 UW-Madison.  Endocrinology Grand Round.  “Efforts to generate a humanized  animal model of type 1 diabetes”
  • 02/07/05 UW-Madison.  Internal Medicine Comprehensive Update.  “Autoimmune Thyroid Disease: clinical and subclinical”
  • 01/25/07 UW-Madison.  Endocrinology Grand Round.  “From insulitis to glucose intolerance. Recapitulating type 1 diabetes in transgenics”
  • 04/03/08 UW-Madison.  Endocrinology Grand Round.  “GADA in LADA of man and mouse”
  • 10/09/08 UW-Madison.  Endocrinology Grand Round.  “Clinical, Subclinical but mostly Non-clinical Autoimmune Thyroid Disease”
  • 10/22/09 UW-Madison.  Endocrinology Grand Round.  “Antigen-specific strategies to regulate autoimmunity in type 1 diabetes of man and mouse”
  • 02/17/11 UW-Madison.  Endocrinology Grand Round.  “Thyroid Autoimmunity and Tumor Immune Surveillance”
  • 02/25/11 UW-Madison.  Medicine Grand Round.  “The Medical and Surgical Management of Thyroid Cancer: a Multidisciplinary Approach”
  • 6/30/11  University of Florida-Gainesville.  Diabetes Center Lectures.  “Antigen-Specific Immunotherapies for Type 1 Diabetes”
  • 12/07/11  University of Kentucky-Lexington.  Endocrinology Grand Rounds. “Thyroid Autoimmunity and Cancer”
  • 1/10/13 UW-Madison.  Endocrinology Grand Rounds.  “Thyroid Cancer Immunoediting”
  • 1/09/14 UW-Madison.  Endocrinology Grand Rounds.  “Record Double Negatives and the Immune Microenvironment of Thyroid Cancer”
  • 3/28/14  University of Toledo.  Medicine Grand Round.  “TO LEaD Or to Follow: The Development of a New Type 1 Diabetes Model”
  • 6/18/15 University of Toledo.  Medicine Grand Round.  “Multidisciplinary Management of Thyroid Cancer”
  • 2016  ProMedica Health System Seminars “i-Diabetes Series” at The Toledo Hospital (4).  Flower Hospital (2) and Monroe Regional Hospital (1).
  • 3/11/2017 ProMedica Health System10th Annual Pharmacology Update.  “New Diabetes Management”
  • 9/01/17 University of Toledo.  Endocrinology Grand Rounds.  “Thyroid Cancer: Genes vs. Immune Microenvironment”  

Patents

  1. US Application # 62/713,827: “A Humanized Animal Model of Spontaneous Autoimmune Diabetes.” University of Toledo, Office of Technology Transfer. 2018.  Background: Although the NOD mouse is the current standard for studies of type I diabetes (T1D), no curative therapies resulting from this model have passed clinical trials. Knock in/out models cannot be used to mimic the total pathophysiology of diabetes. In order to develop a cure for T1D, there is a need for an animal model of human T1D that resembles the human disease and as such exhibits the complications of diabetes.  Invention Description:  Researchers at the University of Toledo have developed a triple transgenic mouse with human T1D susceptibility that closely resembles the human disease and its complications. The mice are a crossing of HLA-DQ8 and human GAD65 for more than 30 generations based on impaired fasting glucose. The result is a transgenic mouse model in which known human beta cell autoantigens are presented to effector T cells in the context of human diabetes susceptibility genes.  Applications: (i) Animal model for autoimmune diabetes disease mechanisms.  (ii) Animal model for the development of antigen-specific immune interventions.  (iii) Animal model for the hyperglycemic complications of diabetes such as nephropathy, neuropathy and retinopathy.  Advantages: (i) Human chronicity of the model allows for therapeutic intervention before the loss of beta cell function.  (ii) These animals show diabetes complications found in the human disease, such as retinopathy,  nephropathy and neuropathy.
  2. US Application # 62/757,313: “Beta-Cell Antigen-Specific Chimeric Antigen Receptor Tregs for Type 1 Diabetes Prevention and Treatment." University of Toledo, Office of Technology Transfer. 2018.  Background: The therapeutic application of regulatory T cells (Tregs) for the treatment of autoimmune diseases is limited by the scarcity of antigen-specific Tregs. If antigen-specific Tregs could be produced on demand against a desire autoimmune target, antigen-specific immune suppression of autoimmune diseases would be achievable. One approach to endow effector T cells with a desired antigen specificity uses chimeric T cell antigen receptors with antibody-type specificity. Cellular therapies with antibody-type specific chimeric antigen receptor (CAR)-redirected cytotoxic T cells has shown efficacy in the treatment of malignancies. Accordingly, employing such chimeric immune receptors to redirect Tregs to sites of autoimmune attack would be a useful therapeutic approach to alleviate a broad scope of diseases in which an uncontrolled autoimmune response plays a major role.  Invention Description: We have developed a transgenic mouse model of type 1 diabetes (T1D) in which human GAD65 is expressed in pancreatic beta cells and human MHC II (DQ8) is expressed in antigen presenting cells. This is an antigen-specific disease model in which antigen presentation activates T cells which generate the downstream events leading to autoimmune diabetes that resembles the human disease.  Described herein is the development of pancreatic beta cell–specific CAR Tregs with preventive and therapeutic capacity against T1D in our animal model.  The present disclosure describes using CAR technology to generate potent, functional, and stable, GAD65 antigen-specific CAR Tregs that can prevent and treat T1D. Also described herein is the antigen-specific CAR Treg development for prevention and treatment of other autoimmune diseases.  Applications: (i) A composition comprising pancreatic beta cell–specific chimeric antigen receptor (CAR) regulatory T cells (Tregs) useful for prevention and treatment of type 1 diabetes (T1D). (ii) A method for preventing and treating diabetes, comprising administering to a diabetic or prediabetic subject an amount effective of the composition above to treat the diabetes.  Advantages: (i) Target-specific immune suppression with preservation of host immune function (immune tolerance) for prevention and treatment of T1D.
  3. UT license application disclosure: “The Noha (nəʊ ˈhaʊ) Manual of Inpatient Diabetes Management” (Author published e-manual on Kindle Direct Publishing platform-Amazon.com).  University of Toledo, Office of Technology Transfer. 2017.

Bibliography

  1. G. Shoshany, K. Kimura, J.C. Jaume, H. Sterman, E. Birbaum, T.A. Stein and J. Levine.  A staged approach to long gap esophageal atresia, employing a spiral myotomy and delayed reconstruction of the esophagus: an experimental study.  J. Ped. Surgery.  23:1218-1221, 1988.
  2. R. Chardavoyne, L. Ratner, J.C. Jaume, T.A. Stein, R. Greenberg, S. Bank and L. Wise.  Safety of endoscopy in the immediate postoperative period following gastric anastomosis.  Surgical Endoscopy.  3:13-15, 1989.
  3. D. Martinez, J.C. Jaume, T.A. Stein and A. Pena.  The effect of costal cartilage resection on chest wall development.  Ped. Surg. International.  5:170:173, 1990.
  4. P. Ellinas, F. Rosner and J.C. Jaume.  Symptomatic hyponatremia.  Amer. J. Med. 89:695-696, 1990.
  5. P. Ellinas, F. Rosner and J.C. Jaume.  Symptomatic hyponatremia associated with psychosis, medications and smoking.  J. Natl. Med. Assoc.  85:135-141, 1993.
  6. J.C. Jaume, M.F. Prummel, W.M. Wiersinga, S.M. McLachlan and B. Rapoport. Thyrotropin receptor autoantibodies recognizing two different epitopes on the TSH receptor: lack of relationship to patient age, sex and ophthalmopathy.  Thyroid.  4:291-295, 1993.
  7. J.C. Jaume, S. Portolano, M.F. Prummel, S.M. McLachlan and B. Rapoport. Molecular cloning and characterization of genes for antibodies generated by tissue-infiltrating B cells in Graves' ophthalmopathy.  J. Clin. Endocrinol. Metab.  78:348-352, 1994.
  8. S.M. McLachlan, M.F. Prummel, J.C. Jaume and B. Rapoport. Immunoglobulin A in Graves' orbital tissue: DNA amplification by polymerase chain reaction.  J. Endocrinol. Invest.  17:247-252, 1994.
  9. J.C. Jaume, S. Portolano, G. Costante, S.M. McLachlan and B. Rapoport. Recombinant thyroid peroxidase-specific autoantibodies: I. How diverse is the pool of heavy and light chain genes in immunoglobulin combinatorial libraries constructed from thyroid tissue-infiltrating plasma cells? Endocrinology.  134:16-24, 1994.
  10. G. Costante, S. Portolano, T. Nishikawa, J.C. Jaume, G.D. Chazenbalk, B. Rapoport and S.M. McLachlan. Recombinant thyroid peroxidase-specific autoantibodies: II. Role of individual heavy and light chains in determining epitope recognition.  Endocrinology.  134:25-30, 1994.
  11. M.F. Prummel, G.D. Chazenbalk, J.C. Jaume, S.M. McLachlan and B. Rapoport.  Profile of Lambda light chain variable region genes in Graves' orbital tissue indicates an active humoral immune response.  Mol. Immunol.  31-11:793-802, 1994.
  12. J.C. Jaume, G. Costante, T. Nishikawa, D.I.W. Phillips, B. Rapoport and S.M. McLachlan.  Thyroid peroxidase autoantibody fingerprints in hypothyroid and euthyroid individuals. I. Cross sectional study in elderly women.  J. Clin. Endocrinol. Metab.  80:994-999, 1995.
  13. J.C. Jaume, A.B. Parker, J.H. Lazarus, R. Hall, G. Costante, S.M. McLachlan and B. Rapoport.  Thyroid peroxidase autoantibody fingerprints in hypothyroid and euthyroid individuals. II. Longitudinal study in post-partum thyroiditis. J. Clin. Endocrinol. Metab. 80:1000-1005, 1995.
  14. T. Nishikawa, J.C. Jaume, S.M. McLachlan and B. Rapoport.  Human monoclonal autoantibodies against the immunodominant region on thyroid peroxidase: Lack of cross-reactivity with related peroxidases or thyroglobulin and inability to inhibit thyroid peroxidase enzymatic activity.  J. Clin. Endocrinol. Metab.  80:1461-1466, 1995.
  15. J.C. Jaume, C.M. Mendel, P.H. Frost, F. Greenspan and C. Laughton.  Extremely low dose of heparin can cause artifactual elevations in the serum free thyroxine concentration as measured by equilibrium dialysis.  Thyroid.  6; 2:79-83, 1996.
  16. J.C. Jaume, C.L. Burek, W.H. Hoffman, N.R. Rose, S.M. McLachlan and B. Rapoport.  Epitopic "fingerprints" of autoantibodies to a major organ-specific autoantigen: Evidence for conservation over time and in families.  Clin. and Experiment. Immunol.  104:115-123, 1996. 
  17. J. Guo, S. Quaratino, J.C. Jaume, G. Costante, M. Londei, S. M. McLachlan and B. Rapoport.  Autoantibody-mediated capture and presentation of autoantigen to T cells via the Fc Epsilon receptor by a recombinant human autoantibody Fab converted to IgE.  J. Immunol. Methods.  195:81-92, 1996.
  18. J.C.  Jaume, S. Portolano, B. Rapoport and S. M. McLachlan.  Influence of the light chain repertoire on immunoglobulin genes encoding thyroid autoantibody Fab from combinatorial libraries.  Autoimmunity.  24:11-23, 1996.
  19. G.D. Chazenbalk, A. Kakinuma, J.C. Jaume, S.M. McLachlan and B. Rapoport.  Evidence for negative cooperativity among human thyrotropin receptors overexpressed in mammalian cells.  Endocrinology.  137:4586-4591, 1996. 
  20. J.C. Jaume, A. Kakinuma, G.D. Chazenbalk, B. Rapoport and S.M. McLachlan.  TSH receptor autoantibodies in serum are present at much lower concentrations than thyroid peroxidase autoantibodies: analysis by flow cytometry.  J. Clin. Endocrinol. Metab.  82:500-507, 1997.
  21. J. Guo, J.C. Jaume, B. Rapoport and S.M. McLachlan.  Recombinant thyroid peroxidase-specific Fab converted to IgG molecules: evidence for thyroid cell damage by IgG1 but not IgG4 autoantibodies.  J. Clin. Endocrinol. Metab.  82:925-931, 1997. 
  22. A. Kakinuma, G.D. Chazenbalk, J.C. Jaume, B. Rapoport and S.M. McLachlan.  The human thyrotropin receptor in a TSH binding inhibition (TBI) assay for thyrotropin receptor autoantibodies.  J. Clin. Endocrinol. Metab.  82:2129-9134, 1997.
  23. G.D. Chazenbalk, K. Tanaka, Y. Nagayama, A. Kakinuma, J.C. Jaume, S.M. McLachlan and B. Rapoport.  The thryrotropin receptor ectodomain contains not one, but two, cleavage sites.  Endocrinology.  138:2893-9899, 1997.
  24. J.C. Jaume, J. Guo, B. Rapoport & S.M. McLachlan.  The epitopic "fingerprints" of thyroid peroxidase-specific Fab isolated from a patient's thyroid gland by the combinatorial library approach resembles that of autoantibodies in the donor's serum.  Clin. Immunol. and Immunopathol.  84:150-157, 1997. 
  25. G.D Chazenbalk, J.C. Jaume, S.M. McLachlan and B. Rapoport.  Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves’ patients sera.  J. Biol. Chem.  272:18959-18965, 1997. 
  26. B. Rapoport, G.D. Chazenbalk, J.C. Jaume, S.M. McLachlan.  The thyrotropin (TSH) receptor: interaction with ligand and autoantibodies. Endocrine Reviews.  19:673-716, 1998. 
  27. G.D. Chazenbalk, J. Guo, Y. Wang, J.S. Hutchison, D. Segal, J.C. Jaume, S.M. McLachlan and B. Rapoport.  A mouse monoclonal antibody to a thyrotropin receptor ectodomain variant provides insight into the exquisite antigenic conformational requirement, epitopes and in vivo concentrations of human autoantibodies. J. Clin. Endocrinol. Metab. 84:702-710, 1999. 
  28. J.C. Jaume, J. Guo, D.L. Pauls, M. Zakarija, J.M. McKenzie, J.A. Egeland, C.L. Burek, N.R. Rose, W.H. Hoffman, B. Rapoport and S.M. McLachlan.  Evidence for genetic transmission of thyroid peroxidase autoantibody epitopic “fingerprints”.  J. Clin. Endocrinol. Metab.  84:1424-1431, 1999. 
  29. J.C. Jaume, J. Guo, Y. Wang, B. Rapoport and S.M. McLachlan.  Cellular thyroid peroxidase (TPO), unlike soluble TPO, induces antibodies in mice that resemble autoantibodies in human autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 84:1651-1657, 1999. 
  30. J.C. Jaume, B. Rapoport and S.M. McLachlan. Lack of female bias in a mouse model of autoimmune hyperthyroidism (Graves’ disease).  Autoimmunity.  29:269-272, 1999.
  31. J. Guo, Y. Wang, J.C. Jaume, B. Rapoport and S.M. McLachlan. Rarity of autoantibody to a major autoantigen, thyroid peroxidase, that interact with denatured antigen or with epitopes outside the immunodominant region. Clin. and Experiment. Immunol.  117:19-29, 1999.
  32. X.-M. Yan, J. Guo, P. Pichurin, K. Tanaka, J.C. Jaume, B. Rapoport and S.M. McLachlan.  Cytokines, IgG subclasses and costimulation in a mouse model of thyroid autoimmunity induced by injection of fibroblasts co-expressing MHC class II and thyroid autoantigens.  Clin. and Experiment. Immunol.  122:170-179, 2000.
  33. W. Khovidhunkit, F. S. Greenspan and J.C. Jaume. Development of overt autoimmune hyperthyroidism in a patient therapeutically immunosuppressed after liver transplantation.  Thyroid. 9:829-832, 2000.
  34. S. Baekkeskov, J. Kanaani, J.C. Jaume, and S. Kash.  Does GAD have a unique role in triggering IDDM?  J. Autoimmun.  15:279-286, 2000. 
  35. T. Wolfe, A. Bot, A. Hughes, U. Möhrle, E. Rodrigo, J. C. Jaume, S. Baekkeskov, and M. von Herrath.  Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent type 1 diabetes: addition of IL-4 increases safety.  Eur. J. Immunol.  32:113-21. 2002. 
  36. J. C. Jaume, S. L. Parry, A.M. Madec, G. Sonderstrup-McDevitt and S. Baekkeskov.  Suppressive effect of GAD65 specific autoimmune B lymphocytes on processing of T cell determinants located within the antibody epitope. J. Immunol. 169:665-72. 2002.
  37. N. Hayakawa, L.D.K.E. Premawardhana, M. Powell, M. Masuda, C. Arnold, J. Sanders, M. Evans, S. Chen, J.C. Jaume, S. Baekkeskov, B. Rees Smith and J. Furmaniak.  Isolation and characterization of human monoclonal autoantibodies to glutamic acid decarboxylase.  Autoimmunity.  35:343-55. 2002.
  38. S.A. Raza, Z. Salam, R.D. Blank, J.C. Jaume, M.K. Drezner,  Severe angioedema-urticaria related to thyroid antigenicity.  Endocr. Pract. 5:445-7. 2004.
  39. M.R. Haymart, D.J. Repplinger, G.E. Leverson, D.F. Elson, R.S. Sippel, J.C. Jaume, H. Chen.  Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J. Clin. Endocrinol. Metab. 2008 Mar;93(3):809-14. Epub 2007 Dec 26, 2007.
  40. S. Mirocha, R. B. Elagin, S. Salamat and J.C. Jaume.  T regulatory cells distinguish two types of primary hypophysitis.  Clin. Exp. Immunol.  2008 Mar;155(3):403-11. Epub 2008 Dec 5.  
  41. M.R. Haymart, S.L. Glinberg, J. Liu, R.S. Sippel, J.C. Jaume and H. Chen. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf).  2009 Sep;71(3):434-9. Epub 2008 Dec 3.
  42. R.B. Elagin, S.Y. Balijepalli, M.J. Diacovo, S. Baekkeskov and J.C. Jaume.  Homing of GAD65 specific autoimmunity and development of insulitis requires expressing of both DQ8 and human GAD65 in transgenic mice.   J. Autoimmun.  2009 Aug;33(1):50-7.  Epub 2009 Mar 16.
  43. K. Todorova-Koteva and J.C.Jaume.  Subcutaneous recombinant human parathyroid hormone (PTH) injection provides a diagnostic tool for identification of non-phenotypically evident pseudohypoparathyroidism by unmasking PTH resistance.  Endo Trends. 2010 Feb;4(16):9-11. 
  44. R.B. Elagin and J.C. Jaume.  Glucose intolerance and diabetes following antigen-specific insulitis in diabetes-susceptible "humanized" transgenic mice.  Biochem Biophys Res Commun. 2010 Apr 23;395(1):99-103.
  45. A. Staii, S. Mirocha, K. Todorova-Koteva, S. Glinberg and J.C. Jaume.  Hashimoto thyroiditis is more frequent than expected when diagnosed by cytology which uncovers a pre-clinical state.  Thyroid Research 2010 Dec 20;3(1):11.
  46. J.C. Jaume and H. Chen.  Inadequate Cytology of Thyroid Nodules.  Repeat it or live with it. Ann Surg Oncol 2011; 18:1222–1223.
  47. K. Todorova-Koteva, K. Wood, S. Imam and J.C. Jaume.  Screening for parathyroid hormone resistance in non-phenotypically evident pseudohypoparathyroidism. Endocr Pract 2012; 11:1-21. 
  48. N. Coorough, K. Hudak, J.C. Jaume, D. Buehler, S. Selvaggi, J. Rivas, R. Sippel, H. Chen.  Non-Diagnostic Fine Needle Aspirations of the Thyroid:  Is the Risk of Malignancy Higher?  J Surg Res 2013;184:746-50.
  49. S. Imam, R.B. Elagin and J.C. Jaume. Diabetes-Associated Dry Eye Syndrome in a New Humanized Transgenic Model of Type 1 Diabetes.  Mol Vis 2013;19:1259-67.
  50. S. Imam, R.G. Mirmira and J.C. Jaume.  Eukaryotic translation initiation factor 5A inhibition alters immune responses in a “humanized” transgenic mouse model of type 1 diabetes.  Am J Physiol Endocrinol Metab. 2014;306:E791-8
  51. R. Paparodis, S. Imam, K. Todorova-Koteva, A. Staii and J.C. Jaume.  Hashimoto thyroiditis pathology and risk for thyroid cancer.  Thyroid. 2014;24:1107-14  Highlighted in NatureEndo Rev. Jun 2014
  52. S. Imam, R. Paparodis, D. Sharma and J.C. Jaume. Lymphocytic Profiling in Cancer and Autoimmunity Provides Clues for Failure of Tumor Immunity. Endocr Relat Cancer. 2014;21:505-16
  53. D.F. Schneider, P.E. Sonderman, M.F. Jones, K.A. Ojomo, H. Chen, J.C. Jaume, D.F. Elson, S.B. Perlman, R.S. Sippel.  Failure of Radioactive Iodine in the Treatment of Hyperthyroidism.  Ann Surg Oncol. 2014;21:4174-80
  54. K-T. Hsu, X-M Yu, A. Audhya, J.C. Jaume, R. Lloyd, S. Miyamoto, T. Prolla and H. Chen.  Novel Approaches in Anaplastic Thyroid Cancer Therapy.  Oncologist. 2014;19:1148-55
  55. R. Paparodis R and J. C. Jaume.  Reanalysis of the data reveal even stronger associations between Hashimoto's thyroiditis and differentiated thyroid cancer. Thyroid. 2015;25:142
  56. J. B. Hao, S. Imam, P. Dar, M. A. Alfonso-Jaume, N. Elnagar and J. C. Jaume.  Extreme Insulin Resistance from Insulin Antibodies (Not Insulin Receptor Antibodies) Successfully Treated with Combination Immunosuppressive Therapy.  Diabetes Care. 2017 Feb;40(2):e19-e20 
  57. I.A. Hajam, P.A. Dar, S, Imam, J.C. Jaume JC and J.H. Lee.  Bacterial flagellin-a potent immunomodulatory agent.  Exp Mol Med. 2017 Sep 1;49(9):e373
  58. J. B. Hao, A. Renno, S. Imam, M. A. Alfonso-Jaume, N. Elnagar and J. C. Jaume.  Development of Type 1 Diabetes after Cancer Immunotherapy.  Endocr Pract Epub 2017 
  59. A. Tiwari, H. Al-Robeh, H Sharma, Z. Ammari, M. Saud Khan, J. C. Jaume.  Steroid-induced diabetic ketoacidosis in patient with type 2 diabetes mellitus. Endocr Pract Epub 2018
  60. Ammari Z, Pak SC, Ruzieh M, Dasa O, Tiwari A, Jaume JC, Alfonso-Jaume MA.  Posttransplant Tacrolimus-Induced Diabetic Ketoacidosis: Review of the Literature. Case Rep Endocrinol. 2018 May 9;2018:4606491. doi: 10.1155/2018/4606491. eCollection 2018.
  61. Alhassan S, Rudoni M, Alfonso-Jaume MA, Jaume JC.  Protracted glycosuria after discontinuation of sodium-glucose cotransporter 2 inhibitors: Implications for weekly dosing and extended risk of euglycemic diabetes ketoacidosis.  J Diabetes. 2018 Dec 15. doi: 10.1111/1753-0407.12885.

  62. Imam S, Dar P, Paparodis R, Almotah K, Al-Khudhair A, Hasan SA, Salim N, Jaume JC.  Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer.  J Immunother Cancer. 2019 Jan 7;7(1):3. doi: 10.1186/s40425-018-0483-y.
  63. Imam S, Prathibha R, Dar P, Almotah K, Al-Khudhair A, Hasan SA, Salim N, Jilani TN, Mirmira RG, Jaume JC.  eIF5A inhibition influences T cell dynamics in the pancreatic microenvironment of the humanized mouse model of Type 1 Diabetes.  Sci Rep. 2019 Feb 7;9(1):1533. doi: 10.1038/s41598-018-38341-5.

  64.  

    S. Imam, M.A. Alfonso-Jaume and J.C. Jaume. Spontaneous autoimmune diabetes in humanized mice carrying human type 1 diabetes susceptibility.  Nat Med (Submitted)

Invited Articles, Books and Book Chapters

  1. S.M. McLachlan, S. Portolano, G.D. Chazenbalk, J.C. Jaume, M.F. Prummel and B. Rapoport. Immunoglobulin genes and autoimmune thyroid disease.  In textbook Frontiers in Endocrinology, Chapter 9; pages 99-103, 1994.
  2. J.C. Jaume.  Endocrine autoimmunity.  In Greenspan’s Basic & Clinical Endocrinology.  10th ed. Gardner DG and Shoback DM, Eds. McGraw-Hill Medical, 2017, Chapter 2; pages 29-48 (Last 6 editions).
  3. H. Chen, D.F. Schneider, H. Mazeh, J.C. Jaume, S. Lubner.  Cancer of the Endocrine System.  In Abeloff’s Clinical Oncology.  5th ed. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB and McKenna WG, Eds.  Churchill Livingstone Elsevier, 2013, Chapter 71, pages 1112-1142.
  4. N. Elnagar, S. Alhassan, F. Khogeer, J. Jun, F. Chaudhry, M. Alfonso-Jaume, J.C. Jaume.  The Noha (nəʊ ˈhaʊ) Manual of Inpatient Diabetes Management.  Kindle Direct Publishing -Amazon.com, 2018. 

abstracts

  1. J.C. Jaume, K. Kimura, L. Ratner, S. Wilkins, A. Dietzik and T.A. Stein.  Functional studies in an isolated bowel segment. American Federation of Clinical Research.  New York, New York 1987 (oral communication).
  2. J.C. Jaume, S. Portolano, M.F. Prummel, S.M. McLachlan and B. Rapoport. Graves' ophthalmopathy: Molecular cloning and characterization of genes for antibodies generated by tissue-infiltrating B cells.  American Thyroid Association.  Tampa, Florida 1993 (oral communication).
  3. J.C. Jaume, S. Portolano, G. Costante, S.M. McLachlan and B. Rapoport. Recombinant thyroid peroxidase-specific autoantibodies: I. How diverse is the pool of heavy and light chain genes in immunoglobulin combinatorial libraries constructed from thyroid tissue-infiltrating plasma cells?  The Endocrine Society.  Anaheim, California 1994.
  4. J.C. Jaume, C.M. Mendel, P.H. Frost, F. Greenspan and C. Laughton.  Extremely low dose of heparin can cause artifactual elevations in the serum free thyroxine concentration as measured by equilibrium dialysis.  American Thyroid Association.  Chicago, Illinois 1994 (oral communication).
  5. J.C. Jaume, S.M. McLachlan, C.L. Burek, W.H. Hoffman, N. Rose and B. Rapoport.  Epitopic "fingerprints" of thyroid peroxidase autoantibodies in Hasimoto's thyroiditis: Evidence for conservation over time and in families.  American Thyroid Association.  Chicago, Illinois 1994 (oral communication).
  6. J.C. Jaume, J. Guo, B. Rapoport & S.M. McLachlan.  Resemblance between the epitopic "fingerprints" of thyroid peroxidase-specific recombinant Fab isolated from a patient's thyroid gland and autoantibodies in the donor's serum.  American Thyroid Association.  San Diego, California 1996 (oral communication).
  7. J. Guo, J.C. Jaume, B. Rapoport and S.M. McLachlan.  Recombinant thyroid peroxidase-specific Fab converted to IgG molecules: evidence for thyroid cell damage by IgG1 but not IgG4 autoantibodies.  American Thyroid Association.  San Diego, California 1996.
  8. J.C. Jaume, J. Guo, D.L. Pauls, M. Zakarija, J.M. McKenzie, J.A. Egeland, C.L. Burek, N.R. Rose, W.H. Hoffman, B. Rapoport and S.M. McLachlan.  Genetic transmission of autoantibody epitopic “fingerprints” to a major organ-specific autoantigen.  American Thyroid Association.  Colorado Springs, Colorado 1997 (oral communication).
  9. W. Khovidhunkit, J.C. Jaume, D.M. Shoback and B. Rapoport.  Severe Graves’ ophthalmopathy twenty eight years after Graves’ disease. American Thyroid Association. Portland, Oregon 1998.
  10. J.C. Jaume, J. Guo, B. Rapoport and S.M. McLachlan. Cell surface thyroid peroxidase (TPO), not soluble TPO, induces antibodies in mice that resemble autoantibodies in human autoimmune thyroid disease. American Thyroid Association. Portland, Oregon 1998 (oral communication).
  11. J. Guo, Y. Wang, J.C. Jaume, B. Rapoport and S.M. McLachlan.  Rarity of autoantibody to thyroid peroxidase that interact with denatured antigen or with epitopes outside the immunodominant region. American Thyroid Association. Portland, Oregon 1998.
  12. J.C. Jaume, S.L. Parry, G. Sonderstrup-McDevitt and S. Baekkeskov. Naturally processed autoantibody-autoantigen complex generates specific T cell epitope that activates MHC restricted T cells more efficiently than autoantigen alone.  BMS/UCSF.  Point Reyes, California 1998.
  13. J.C. Jaume. Thyrotropin receptor autoantibodies not interfering with thyrotropin binding (“neutral”) detected in a patient with Hashimoto’s hypothyroidism and Graves’ ophthalmopathy.  American Thyroid Association.  Palm Beach, Florida 1999.
  14. J.C. Jaume, S. L. Parry, A.M. Madec, W. Furmaniak, G. Sonderstrup-McDevitt and S. Baekkeskov GAD65-specific B cells suppress presentation of immunodominant T cell epitopes residing in their antibody binding site while enhancing presentation of distant epitopes. American Diabetes Association. San Francisco, California 2002.
  15. J.C. Jaume, S.arah L. Parry, A. M. Madec, G. Sonderstrup-McDevitt and S. Baekkeskov.  How The T Cell Repertoire In Type 1 Diabetes Is Shaped By Antigen Presenting Autoimmune B Cells.  The Endocrine Society.  San Francisco, California 2002.
  16. J.C. Jaume.  Efforts to generate a humanized mouse model for type 1 diabetes. UCSF/Diabetes Center Symposium. Tiburon, California 2004.
  17. S. Mirocha, S. Salamat and J.C. Jaume.  Lymphogranulomatous hypophysitis, an intermediate state on the natural evolution of the disease or a new entity?  The Endocrine Society.  Toronto, Canada 2007.
  18. R.B. Elagin, S.Y. Balijepalli, M.J. Diacovo, S. Baekkeskov and J.C. Jaume*.  Antigen specific insulitis in “humanized” transgenic mice. The Endocrine Society. Toronto, Canada 2007. (*oral communication in new BENCH TO BEDSIDE session).
  19. M.R. Haymart, D. Repplinger, J.C. Jaume and H. Chen. What’s in a number? The role of TSH in predicting thyroid cancer. American Thyroid Association.  New York, New York 2007    
  20. R.B. Elagin and J.C. Jaume*.  Glucose intolerance from antigen specific insulitis in “humanized” transgenic mice.  The Endocrine Society.  San Francisco, California 2008. (*oral communication in new BENCH TO BEDSIDE session).
  21. M.R. Haymart, S.L. Glinberg, J. Liu, R.S. Sippel, J.C. Jaume and H. Chen.  Is the association of cancer and higher TSH a matter of age? American Thyroid Association. Chicago, Illinois 2008
  22. A. Staii and J.C. Jaume.  Unexpected High Prevalence of Hashimoto’s Thyroiditis Diagnosed by Ultrasound-Guided FNA.  The Endocrine Society.  Washington, DC 2009.
  23. R.B. Elagin and J.C. Jaume*.  Type 1 Diabetes Antigen-Specific “Humanized” Transgenic Model. Evidence for Regulatory T cell Controlled Insulitis.  The Endocrine Society.  Washington, DC 2009. (*oral communication in new BENCH TO BEDSIDE session)
  24. 24.  K. Todorova-Koteva and J.C. Jaume.     Subcutaneous recombinant human parathyroid hormone (PTH) injection provides a diagnostic tool for identification of non-phenotypically evident pseudohypoparathyroidism by unmasking PTH resistance.  American Diabetes Association.  New Orleans, LU 2009.
  25. K. Todorova-Koteva, A. Staii and J. C. Jaume*.  Non-Clinical (Euthyroid) Hashimoto Thyroiditis as a Risk Factor for Thyroid Cancer.  The Endocrine Society.  San Diego, CA 2010.  *Presidential Award Winner.
  26. R. B. Elagin and J. C. Jaume. Diabetes-Associated Dry Eye Syndrome in a ‘Humanized’ Transgenic Model of Type 1 Diabetes.  The Endocrine Society.  San Diego, CA 2010.
  27. S. Sirinvaravong, S. Imam and J. C. Jaume. Simultaneous Medullary and Papillary Thyroid Cancer.  Cancer Stem Cell Prototype or Coexistence?  American Thyroid Association.  Palm Springs, CA 2011.
  28. R. Paparodis, K. Naraharisetty, and J. C. Jaume. Does thyroid function in Hashimoto’s influence thyroid cancer development?  The Endocrine Society.  Houston, TX 2012.
  29. S. Imam, R. G. Mirmira and J. C. Jaume.  Eukaryotic Translation Initiation Factor 5A Inhibition Alters Immune Responses in a “Humanized” Transgenic Mouse Model of Type 1 Diabetes. American Diabetes Association. Chicago, IL 2013.
  30. S. Imam, and J. C. Jaume.  Thyroid cancer immunoediting by regulatory double negative (DN) T cells. American Association of Cancer Research. Washington, DC 2013. (Late Breaking Abstract)
  31. N. Chongkrairatanakul, H. Chen and J. C. Jaume.  Risk of Thyroid Cancer in Follicular Lesion of Undetermined Significance Differs Significantly Among Academic Institutions: Should Management Be Tailored to Local Experience?  The Endocrine Society.  San Francisco, CA 2013.
  32. R. Paparodis and J. C. Jaume. Functional Hashimoto Thyroiditis is Associated with Increased Risk for Thyroid Cancer.  The Endocrine Society.  San Francisco, CA 2013.
  33. R. Paparodis and J. C. Jaume. High Titers of Thyroid Peroxidase Antibodies appear Protective for Thyroid Cancer in Patients with Hashimoto Thyroiditis.  The Endocrine Society.  San Francisco, CA 2013.
  34. R. Paparodis and J. C. Jaume. Repeat FNA Biopsies for Thyroid Nodules: Risk Factors for Differentiated Thyroid Cancer. The Endocrine Society.  San Francisco, CA 2013.
  35. S. Pandey, V. L.  Cryns and J. C. Jaume.  Decade of Hashimoto thyroiditis Followed by Graves disease.  The Endocrine Society.  San Francisco, CA 2013. 
  36. D. F. Schneider, P. E. Sonderman, M. F. Jones, K. A. Ojomo, H. Chen, J. C. Jaume, D. F. Elson, S. B. Perlman and R.S. Sippel. Failure of Radioactive Iodine in Treatment of Hyperthyroidism.  American Thyroid Association.  San Juan de Puerto Rico, PR 2013.
  37. S. Thida S. Imam, R. McKenney and J. C. Jaume. Does Interferon Beta 1a (IFNβ 1a) Treatment for Multiple Sclerosis Alter the Immune Microenvironment of Papillary Thyroid Cancer (PTC)?  American Thyroid Association.  San Juan de Puerto Rico, PR 2013.
  38. R. McKenney and J. C. Jaume.  Extramedullary Plasmacytoma of the Thyroid Diagnosed with Ultrasound-Guided Core Needle Biopsy.  American Thyroid Association.  San Juan de Puerto Rico, PR 2013.
  39. R. Paparodis and J. C. Jaume.  High Titers of Thyroid Peroxidase, Thyroglobulin and TSH-Receptor Antibodies Appear Protective for Thyroid Cancer in Patients with Graves Disease.  The Endocrine Society.  Chicago, IL 2014. 
  40. R. Paparodis and J. C. Jaume.  Thyroid Cancer Features in the Setting of Graves Disease.  The Endocrine Society.  Chicago, IL 2014.  
  41. S. Thida, N. Chongkrairatanakul and J. C. Jaume. The Risk of Malignancy and Outcome In Thyroid Nodules Categorized as Follicular Lesion of Undetermined Significance (FLUS).  The Endocrine Society.  Chicago, IL 2014.
  42. S. Pandey and J. C. Jaume.  Risk of Thyroid Cancer in Prospectively Followed Euthyroid Hashimoto Thyroiditis.  The Endocrine Society.  Chicago, IL 2014.
  43. S. Imam, R. Paparodis, D. Sharma and J. C. Jaume*. Presence of NK Cells and M1/M2 Macrophage Ratio Provides Clues for Protection Against Thyroid Cancer in Graves Disease.  The Endocrine Society.  Chicago, IL 2014. (Late Breaking Abstract and *Presidential Award Winner)
  44. S. Imam, P. S. Kumar, R. G. Mirmira and J. C. Jaume.  Eukaryotic Translation Initiation Factor 5A Inhibition Reduces Proinflamotory Cytokines and ER Stress in Beta Cell Microenvironment in a Humanized Transgenic Model of Type 1 Diabetes.  American Diabetes Association.  San Francisco, CA 2014.  (Late Breaking Abstract)
  45. J. B. Hao, A. Schuna and J. C. Jaume. Extreme Insulin Resistance from Insulin Antibodies (not Insulin Receptor Antibodies) Successfully Treated with Combination Immunosuppresive Therapy. The Endocrine Society.  San Diego, CA 2015.
  46. S. Imam, R. Paparodis and J. C. Jaume.  Does Macrophage Plasticity in Thyroid Microenvironment Decide the Fate of Thyroid cancer?  The Endocrine Society.  San Diego, CA 2015.  
  47. J. B. Hao, S Thida, S Sirinvaravong, A Day and J. C. Jaume*.  Early Adulthood Onset Diabetes: T1DM, T2DM, Latent Autoimmune Diabetes of Adults, does it really matter?  The Endocrine Society.  Boston, MA 2016.  *Helmsley Charitable Abstract Award in T1D
  48. A. Renno, J.B. Hao, S. Imam and J.C. Jaume. An FDA Approve Drug that Causes Type 1 Diabetes.  Is it Just Coincidence?  The Endocrine Society.  Boston, MA 2016. 
  49. R.D. Paparodis, D. Bantouna, S. Imam and J.C. Jaume. The Risk of Thyroid Cancer Depends on the Type of Autoimmune Thyroid Disease Associated with It.  The Endocrine Society.  Orlando, FL 2017.
  50. G. Antoniou, S. Kasikis, C. Chourpiliadis, D. Bantouna, J.C. Jaume and R.D. Paparodis.  Patients with History of Fractures Have Profound Abnormalities in Bone Metabolism and Thyroid Function.  The Endocrine Society.  Orlando, FL 2017.
  51. R.D. Paparodis, D. Bantouna, S. Imam and J.C. Jaume. Higher Serum TSH Is Associated with Differentiated Thyroid Cancer Risk, Only in the Absence of Thyroid Autoimmunity. The Endocrine Society.  Orlando, FL 2017.
  52. S. Imam, P Dar, K. Almotah, R.D. Paparodis and J.C. Jaume.  Macrophage-Natural Killer Cell Cross-Talk: Implications for Thyroid Cancer.  The Endocrine Society.  Orlando, FL 2017.
  53. R.D. Paparodis, D. Bantouna, S. Imam and J.C. Jaume. Comparison of Features of Tumor Aggressiveness Between Thyroid Papillary Microcarcinomas and Macrocarcinomas.  The Endocrine Society.  Orlando, FL 2017.
  54. G. Antoniou, S. Kasikis, C. Chourpiliadis, D. Bantouna, J.C. Jaume and R.D. Paparodis.  Biochemically Euthyroid Patients with Symptoms Attributable to Thyroid Disease, Have a High Prevalence of Abnormal Bone Density and Fractures.  The Endocrine Society.  Orlando, FL 2017. 
  55. M.S. Khan, J.B. Hao, F. Chaudhry, A. Tiwari, H. Sharma and J.C. Jaume.  Response to IVIG Leads to Diagnosis of Stiff Person Syndrome in a Patient with Limbic Encephalitis and GAD65 Autoantibodies without Diabetes.  The Endocrine Society.  Orlando, FL 2017.
  56. O. Oraibi, L.I. Wharry, A.A. Lynn, F. Chaudhry, J.C. Jaume, J.Y. Jun.  A Case of Adrenal Malignant Pheochromocytoma Combined with Primary Malignant Lymphoma. The Endocrine Society.  Chicago, IL 2018
  57. S. Imam, K.I. Almotah, P. Dar, A.S. AlKhudhair, R. Lamendella, J.C. Jaume.  Prolonged Nursing (late Weaning), Delays The Onset Of Type 1 Diabetes In The Genetic Susceptible Humanized Mouse Model Of T1D.  The Endocrine Society.  Chicago, IL 2018
  58. C.P. Chourpiliadis, G. Antoniou, S. Kasikis, P-C.P. Koukoutsidi, L-N. Diamantopoulos, D. Bantouna, J.C. Jaume, R. Paparodis.  Fractures of Any Kind, at Any Age Predict Low Bone Mineral Density and Osteoporosis. The Endocrine Society.  Chicago, IL 2018
  59. S. Alhassan, M. Rudoni, J.C. Jaume.  Prolonged Glucosuria After Discontinuation Sglt2 Inhibitors: Implications For Weekly Dosing And Extended Risk Of Euglycemic Diabetes Keto-acidosis.  The Endocrine Society.  Chicago, IL 2018
  60. R. Paparodis, D. Bantouna, S. Imam, J.C. Jaume. The Impact of Follicular Variant Papillary Thyroid Cancer (FV-PTC) in Features of Tumor Aggressiveness in Thyroid Papillary Microcarcinomas and Macrocarcinomas.  The Endocrine Society.  Chicago, IL 2018
  61. S. Kasikis, G. Antoniou, P-C. P. Koukoutsidi, C.P. Chourpiliadis, D. Bantouna, M. Panagiota, J.C. Jaume, R. Paparodis.  Bone Mineral Density Abnormalities in Patients with Biochemically Euthyroid Thyroiditis.  The Endocrine Society.  Chicago, IL 2018
Last Updated: 2/12/20